Locally advanced pancreatic cancer
Conditions
Interventions
As a general rule, the first course is hospitalized and performed, but after the second course, outpatient treatment is possible at the discretion of the attending physician while observing the patien
Sponsors
Uwagawa Tadashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have been confirmed by histological or cytological examination to have pancreatic cancer. 2) Patients with locally advanced pancreatic cancer who do not have distant metastasis and the tumor has spread to the surrounding arteries and veins, making curative resection difficult. 3) Patients who have not received prior treatment for this disease prior to enrollment 4) Patients whose age at registration is 20 years or older and under 80 years old 5) Patients with Performance status (ECOG) of 0,1 6) Patients who are expected to survive for more than 3 months from the start of treatment 7) Patients who retain the functions of major organs (bone marrow, liver, kidneys, lungs, etc.) 8) Patients with sufficient urine output 9) Patients who can take orally 10) Patients with written consent
Exclusion criteria
Exclusion criteria: 1) Patients with non-curative factors during radical resection 2) Patients with overt pulmonary fibrosis or interstitial pneumonia 3) Patients with active infections (HB, HCV, HIV infections, etc.) 4) Patients with heart failure, angina, arrhythmia and myocardial infarction within 6 months of onset that are difficult to control despite treatment 5) Patients with uncontrollable diabetes 6) Patients with watery diarrhea 7) Patients using flucytosine and phenytoin 8) Pregnant women, lactating and patients with or willingness to become pregnant 9) Patients with severe drug allergies 10) Patients with active double cancer (not applicable to cases 5 years after complete cure) 11) Patients with other serious complications 12) Patients with severe neuropsychiatric symptoms and renal disorders 13) Patients with hearing impairment 14) Chickenpox patients 15) Patients with prior treatment history for this disease 16) Other patients who the doctor in charge judged to be inappropriate for conducting this study safely
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal radiation dose Transition rate to radical surgical resection | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse drug/radiation reactions Progression-free survival in patients with inoperable conversion and BR pancreatic cancer inoperable Recurrence free survival in patients undergoing Conversion surgery and BR pancreatic cancer surgery Response rate Disease control rate 1-year and 2-year survival rates Tumor markers: Changes in serum CEA, CA19-9, DUPAN, etc. | — |
Contacts
Public ContactTadashi Uwagawa
The Jikei University Hospital
Outcome results
None listed